Manu Chakravarthy, vice president at Genentech, said, Amylin helps people feel satisfied after a meal, but it doesn't make them feel like they don't want to eat at all, calling it a subtle but important difference. James List, head of internal medicine research at Pfizer, who is conducting research on amylin, said, If there is clinical differentiation, we can fill unmet gaps in the obesity drug market, adding, Even if we enter the market later, it is necessary to develop a differentiated product. Eli Lilly and Novo Nordisk, which already dominate the market, have also begun developing amylin-based therapies
Semaglutide hasnt become ineffective
Current literature regarding the use of GLP-1 RMs for dumping syndrome is limited, with one systematic review including 31 patients across heterogeneous study designs and assessing symptomatic postprandial hypoglycaemia as a surrogate investigation for late dumping syndrome after MBS [13]
Although biotin occurs in the body naturally, genetic disposition, long-term antibiotic use, or prenatal supplements may cause our reserves to dip
Semaglutide is an FDA-approved medication that mimics the glucagon-like peptide-1 (GLP-1) hormone in the body